Annals of African Medicine

Ann Afr Med. 16(4): 181-185

Tumor-associated Macrophages, Angiogenesis, and Tumor Cell Migration in Oral Squamous Cell Carcinoma

Samuel E. Udeabor¹², Akinyele O. Adisa²³, Anna Orlowska², Robert A. Sader², Shahram Ghanaati²

1. Department of Oral and Maxillofacial Surgery, College of Dentistry, King Khalid University, Abha, Saudi Arabia

2. Frankfurt Orofacial Regenerative Lab, Department of Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Medical Center of Goethe University Frankfurt am Main, Germany

3. Department of Oral Pathology, College of Medicine, University of Ibadan, Nigeria

Address for correspondence: Dr. Shahram Ghanaati, Frankfurt Orofacial Regenerative Lab, Department of Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Medical Center of Goethe University, Frankfurt am Main, Germany. E-mail: shahram.ghanaati@kgu.de

Copyright: © 2017 Annals of African Medicine

DOI: 10.4103/aam.aam_8_17

Published in print: Oct-Dec2017

Abstract

Objective:

To investigate the relationship between tumor-associated macrophages (TAMs), neovascularization, and tumor cell migration in oral squamous cell carcinoma (OSCC) of an African subpopulation.

Materials and Methods:

Twenty OSCC paraffin blocks underwent immunohistochemistry to TAM1 (CCR7), TAM2 (CD206), Twist, E-cadherin, N-cadherin, and CD34. The relative percentage of CCR7 + and CD206 + cells to overall immune cell population was calculated for three high power fields and an average was taken. TAM-related microvessel density (MVD) was determined as the mean of the three recorded values. Cases that had no CD34 + vessels adjacent to the TAMs region were regarded as having an MVD score of 0.

Results:

Ten cases (50%) expressed greater CCR7 activity than CD206, seven cases (35%) expressed approximately equal activity of CCR7 and CD206, while three cases (15%) expressed greater activity of CD206 than CCR7. Twist expression was strong in some cases with strong N-cadherin and weak E-cadherin, but the expression of Twist was not consistently high in all cases that expressed strong N-cadherin and weak E-cadherin.

Conclusions:

TAMs distribution suggested antitumor activity and the potential for tumor metastasis was only partly due to Twist-mediated epithelial–mesenchymal transition.

INTRODUCTION

The tumor microenvironment has such a great impact on the status of the tumor cells that it has been reported that a normal microenvironment can prevent malignant cells from committing to neoplasia and even reverse the malignant phenotype though the cancer cells retain their mutations.[1] The progression of tumors is characterized by the recruitment of innate and adaptive immune cells through cytokines and chemokines to the tumor site, and macrophages are especially abundant during tumor evolution.[2] Macrophages are hematopoietic cells in the innate immune system, which phagocytose cellular debris and foreign particles, and present antigens to T-cells during normal immune responses. They are influenced by their microenvironment during normal function and are differently activated depending on the tissue and the microenvironment. Unlike macrophages in a normal, healthy tissue or wound-healing environment, tumor-associated macrophages (TAMs) are modified in the context of the tumor microenvironment and lose the ability to phagocytize cancer cells or present tumor antigens to T-cell, thus becoming active co-conspirators in cancer progression.[3]

The role of TAMs is controversial because there is evidence for their participation in protumor as well as antitumor activities.[4] TAMs release several potent pro-angiogenic cytokines and growth factors such as vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-8. They also express some angiogenesis-modulating enzymes including matrix metalloproteinase-2 (MMP-2) and MMP-9.[5] Therefore, TAMs also support tumor growth by stimulating neovascularization that is essential for tumor progression.

It is also reported that TAMs appear to play roles in the release of metastatic cells from the primary tumor as well as the establishment of secondary tumors at distant sites.[6] TAMs actually exist in two distinctive states: one is the classically activated (M1) state and the other is the otherwise activated (M2) state. M1 macrophages possess antitumor activity, whereas M2 macrophages support tumor invasion and metastasis.[7] As these epithelial cells prepare for migration or invasion, they tend to go through the phase of epithelial–mesenchymal transition (EMT). The relative amount of change in this phase can be measured by E-cadherin (epithelial marker) and N-cadherin (mesenchymal marker).

We will investigate the relationship between TAMs, neovascularization, and tumor cell migration in oral squamous cell carcinoma (OSCC) with specific reference to an African subpopulation, to understand more of its biology. This is because OSCC in Sub-Saharan Africa occurs in younger individuals as compared to the Caucasian population, and only has weak association to established carcinogens.[8]

MATERIALS AND METHODS

Twenty formalin-fixed paraffin-embedded (FFPE) blocks of OSCC cases from the Oral Pathology Department of the University College Hospital, University of Ibadan, Nigeria, were sectioned and stained with hematoxylin and eosin for reevaluation and inclusion. At the Frankfurt Orofacial Regenerative Medicine Laboratory, Department for Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Medical Center of the Goethe University Frankfurt, Frankfurt am Main, Germany, sections were prepared for immunohistochemistry to TAM1, TAM2, Twist, E-cadherin, N-cadherin, and anti-CD34 antibody staining using the manufacturer's specification. All the FFPE blocks were each cut into six sections, deparaffinized using xylene, and hydrated with alcohol. The tissue was immersed in heat-induced epitope retrieval 10 mMol citrate buffer pH 6.0 (TA-250-PM1X), diluted 1:100 with distilled water, and incubated at 95°C for 20 min. They were cooled in the buffer for 20 min and then rinsed in phosphate buffered saline for 5 min. Positive and negative controls were employed for each antibody. Thermo-Scientific peroxidase blocking reagent was added to each section for 15 min, and the sections were rinsed in 0.1% TBST for 5 min. The specimens were incubated for 60 min with the antibodies; Abcam mouse monoclonal anti-CCR7 antibody (Y59) (ab32527) (dilution 1:1000), Abcam rabbit polyclonal anti-CD206 antibody (anti-mannose receptor antibody) (ab64693) (dilution 1:1000), Dako mouse monoclonal anti-CD34 antibody QBEnd-10 (M7165) (dilution 1:25), Abcam mouse monoclonal anti-Twist antibody (10E4E6) (ab175430) (dilution 1:100), Abcam mouse monoclonal anti-E-cadherin antibody (HECD-1) (ab1416) (dilution 1:200), and Abcam mouse monoclonal anti-N-cadherin antibody (5D5) (ab98952) (dilution 1:200). They were then rinsed with TBST, followed by incubation with prediluted (ready-to-use) UltraVision Quanto Detection System/Horseradish peroxidase for 15 min. An appropriate volume of 1 ml of diaminobenzidine substrate with one drop of diaminobenzidine chromogen was added to cover the slides, followed by incubation in a humidity chamber for 5 min. The sections were then immersed in aqueous Gill's hematoxylin for 10 s and rinsed in distilled water for 5 min. The tissue was dehydrated and subsequently rinsed with xylene. DPX was applied, and a cover slip was placed. Cytoplasmic/membrane staining was taken as positive for E-cadherin, N-cadherin, CCR7, CD206, and CD34. Nuclear brown staining was considered as positive for Twist.

Quantification and scoring of CCR7 and CD206

Stained tissue sections were analyzed using a semiquantitative method with a light microscope at ×400 magnification. Three representative high power fields (hpf) showing maximum immunopositivity adjacent to tumor cells was selected for scoring by cell counting. The relative percentage of CCR7 + and CD206 + cells in relation to overall cellularity was calculated for each hpf, and the final score was taken as an average of the three hpf. Final scores for CCR7 and CD206 were classified as: <5%, 5%–25%, >25%–50%, and >50% (Steidl et al., 2010).

Quantification and scoring of Twist, N-cadherin, and E-cadherin

The Sinicrope scoring method was used to evaluate both the intensity of the immunohistochemical staining and the proportion of the stained epithelial cells. The staining intensity was classified as weak, moderate, or strong. The positive cells were quantified as a percentage of the total number of epithelial cells and assigned to one of the five categories (0, <5%; 1, 5%–25%; 2, 26%–50%; 3, 51%–75%; 4, >75%). The percentage of positivity of the tumor cells and the staining intensities were then multiplied to generate an immunoreactive score. The product of the proportion and intensity scores were calculated such that a final score of 0 indicated no expression, 0–4 indicated weak expression, 5–8 indicated moderate expression, and 9–12 indicated strong expression.

Quantification and scoring of CD34

TAM-related microvessel density (MVD) was evaluated by choosing three fields, with the highest number of vessels at ×10, adjacent to the TAMs to assess association of the vessels to the macrophages. Then, counting the CD34-positive vessels at ×40 magnification, the MVD was calculated as the mean of the three recorded values. Cases that had no CD34+ vessels adjacent to the TAMs region were regarded as having an MVD score of 0.

All slides were viewed with a Nikon ECLIPSE 80i microscope (Nikon, Tokyo, Japan), and microphotographs of the stained sections were recorded with a connected digital camera DS-Fi1 together with a Nikon digital sight control unit (Nikon, Tokyo, Japan).

RESULTS

Twenty OSCC cases were evaluated comprising 4 (20%) well-differentiated squamous cell carcinomas, 15 (75%) moderately differentiated carcinomas, and 1 (5%) poorly differentiated carcinoma. Case-by-case review for percentage expression of CD206 and CCR7 was done, and 10 cases (50%) expressed greater CCR7 activity than CD206, 7 cases (35%) expressed approximately equal activity of CCR7 and CD206, while 3 cases (15%) expressed greater activity of CD206 [Figure 1] than CCR7 [Table 1].

Figure 1View larger versionFigure 1. CD206-positive cells (25%–50%) adjacent to malignant epithelial nest of oral squamous cell carcinoma

See full tableTable 1. Oral squamous cell carcinoma expression of CD206, CCR7, Twist, N-cadherin, E-cadherin, and CD34

For the same cases, every time, that Twist was strongly expressed (5 cases) [Figure 2], N-cadherin was also strongly expressed [Figure 3] (4 cases strong and 1 case moderate), and E-cadherin was weakly/moderately expressed (2 cases weak and 3 cases moderate). Contrariwise every time, that Twist was weakly expressed (5 cases), N-cadherin was strongly/moderately expressed (2 cases strong and 3 cases moderate), and E-cadherin was weak (3 cases), moderate (1 case), and not expressed at all (1 case) [Table 1].

Figure 2View larger versionFigure 2. Twist ++ positive malignant epithelial cells

Figure 3View larger versionFigure 3. N-cadherin +++ positive malignant epithelial cells

The average MVD for three categories of N-cadherin was calculated. For weak N-cadherin expression, MVD = 4.3; for moderate N-cadherin expression, MVD = 7.0; and for strong N-cadherin expression, MVD = 10.3.

DISCUSSION

Most of our cases expressed higher CCR7 than CD206 on a case-by-case evaluation, signifying a higher activity of TAM1 as compared to TAM2 and hence suggesting good prognosis. This describes a tumor microenvironment that is mostly antitumor, unlike the submission by Lewis and Pollard,[3] where the microenvironment is a co-conspirator to promote tumor progression. Although most cases could be said to have good prognosis in this study based on the microenvironment biology, the neoplastic cells displayed relatively strong N-cadherin expression, which promotes metastasis and angiogenesis and is associated with poor survival.[9] Consequently, we can conclude that the patients’ outlook is still not so good. Our cases also showed a higher MVD average when N-cadherin expression was strong, which is in agreement with the report by Mariotti et al.[9]

The EMT is a biological event in which epithelial cells lose many of their phenotypic features and gain extra properties typical of mesenchymal cells.[10] However, abnormal expression of cadherins, or cadherin switching, is a key event in the EMT of some cancers, including OSCC.[11] In our study, most cases expressed N-cadherin while E-cadherin was decreased, this is a mark of EMT. On the contrary, in a study by Costa et al.,[10] none of their OSCC cases expressed N-cadherin but a reduction of E-cadherin, especially on the invasive front, and they interpreted this also as EMT. This is because not only the loss of E-cadherin but also the expression of N-cadherin increases the mobility of epithelial cells and its capacity for invasion.[10]

Twist expression was strong in some cases with strong N-cadherin and weak E-cadherin, supporting the concept of Twist-mediated EMT. However, we noted that the expression of Twist was not consistently high in all cases that expressed strong N-cadherin and weak E-cadherin. This suggests that EMT was being mediated through some other means, and actually, it has been reported that the presence of Twist, although weak, can stimulate Slug (a member of Snail family of zinc finger transcription factors) and induce an E- to N-cadherin switch.[12] This advises the decision that in treatment planning targeting EMT mediators, both Twist and Slug could form therapeutic foci.

CONCLUSION

We found that TAMs were mostly antitumor and that the potential for tumor metastasis was partly due to Twist-mediated EMT. For OSCC in this cohort, management should include analysis of both the existing immune competence of the tumor microenvironment and the dynamics affecting metastasis of the neoplastic cells.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Acknowledgment

We wish to thank Mrs. Verena Hoffmann and Mr. Babajide Okedere for all the technical assistance provided during this study.

Articles from Annals of African Medicine are provided here courtesy of Wolters Kluwer/Medknow Publications

PMC Copyright Notice

The articles available from the PMC site are protected by copyright, even though access is free. Copyright is held by the respective authors or publishers who provide these articles to PMC. Users of PMC are responsible for complying with the terms and conditions defined by the copyright holder.

Users should assume that standard copyright protection applies to articles in PMC, unless an article contains an explicit license statement that gives a user additional reuse or redistribution rights. PMC does not allow automated/bulk downloading of articles that have standard copyright protection.

See the copyright notice on the PMC site, https://www.ncbi.nlm.nih.gov/pmc/about/copyright/, for further details and specific exceptions.

REFERENCES

Bissell MJ, Radisky D, authors. Putting tumours in context. Nat Rev Cancer. 2001;1:46–54. [PubMed]

Noy R, Pollard JW, authors. Tumor-associated macrophages: From mechanisms to therapy. Immunity. 2014;41:49–61. [PubMed]

Lewis CE, Pollard JW, authors. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–12. [PubMed]

Bingle L, Brown NJ, Lewis CE, authors. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol. 2002;196:254–65. [PubMed]

Lewis CE, Leek R, Harris A, McGee JO, authors. Cytokine regulation of angiogenesis in breast cancer: The role of tumor-associated macrophages. J Leukoc Biol. 1995;57:747–51. [PubMed]

Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S, authors. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol. 2004;99:1667–74. [PubMed]

Richards DM, Hettinger J, Feuerer M, authors. Monocytes and macrophages in cancer: Development and functions. Cancer Microenviron. 2013;6:179–91. [PubMed]

Faggons CE, Mabedi C, Shores CG, Gopal S, authors. Review: Head and neck squamous cell carcinoma in sub-Saharan Africa. Malawi Med J. 2015;27:79–87. [PubMed]

Mariotti A, Perotti A, Sessa C, Rüegg C, authors. N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs. 2007;16:451–65

Pyo SW, Hashimoto M, Kim YS, Kim CH, Lee SH, Johnson KR, et al., authors. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome. J Craniomaxillofac Surg. 2007;35:1–9. [PubMed]

Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR, authors. Cadherin switching. J Cell Sci. 2008;121(Pt 6):727–35. [PubMed]

Zhang J, Cheng Q, Zhou Y, Wang Y, Chen X, authors. Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: Correlations with poor prognosis. Oral Oncol. 2013;49:1043–50. [PubMed]

[Back]

Figure 1.

CD206-positive cells (25%–50%) adjacent to malignant epithelial nest of oral squamous cell carcinoma

[Back]

[Back]

Table 1.

Oral squamous cell carcinoma expression of CD206, CCR7, Twist, N-cadherin, E-cadherin, and CD34

Grade of cancer | CD206 (%) | CCR7 (%) | Twist | N-cadherin | E-cadherin | CD34 (MVD)
WDSCC | 5-25 | <5 | None | Weak | None | 0
5-25 | >50 | Weak | Strong | None | 0
5-25 | >50 | Weak | Moderate | Weak | 14
<5 | >50 | Weak | Moderate | Weak | 8
MDSCC | <5 | <5 | None | Weak | Weak | 0
>50 | >50 | Weak | Strong | Moderate | 22
25-50 | >50 | Strong | Strong | Weak | 4
25-50 | >50 | None | Strong | Weak | 16
<5 | >50 | Moderate | Strong | Moderate | 8
<5 | >50 | None | Weak | Weak | 0
>50 | >50 | Moderate | Moderate | None | 0
25-50 | 25-50 | Weak | Moderate | Weak | 0
>50 | >50 | None | Weak | Moderate | 17
>50 | 5-25 | Strong | Strong | Weak | 8
>50 | >50 | Strong | Moderate | Moderate | 15
>50 | 5-25 | None | Strong | Moderate | 8
<5 | >50 | Strong | Strong | Moderate | 19
<5 | 5–25 | Strong | Strong | Moderate | 8
>50 | >50 | Moderate | Moderate | Weak | 5
PDSCC | <5 | >50 | Moderate | Strong | Weak | 24

WDSCC=Well-differentiated squamous cell carcinoma, MDSCC=Moderately differentiated squamous cell carcinoma, PDSCC=Poorly differentiated squamous cell carcinoma, MVD=Microvessel density

[Back]

[Back]

Figure 2.

Twist ++ positive malignant epithelial cells

[Back]

[Back]

Figure 3.

N-cadherin +++ positive malignant epithelial cells

[Back]